The "bone morphogenic proteins" pathways in bone and joint diseases: Translational perspectives from physiopathology to therapeutic targets

Cytokine and Growth Factor Reviews

Volumn 24, Issue 1, 2013, Pages 69-81

  Biver, Emmanuel ^a,b,c   Hardouin, Pierre ^a   Caverzasio, Joseph ^c  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bone morphogenic proteins; Fracture healing; Osteoarthritis; Osteoporosis; Signaling pathways

Indexed keywords

ACTIVIN RECEPTOR 2; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BORTEZOMIB; DEXAMETHASONE; EPOXOMICIN; FC RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTACYSTIN; NOGGIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; OSTEOGENIN; OSTEOPROTEGERIN; OSTHOLE; OXYTOCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; SOTATERCEPT; ZOLEDRONIC ACID;

ANKYLOSING SPONDYLITIS; ARTHROPATHY; BONE DEFECT; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE REGENERATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG INTERMITTENT THERAPY; FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; HETEROTOPIC OSSIFICATION; HUMAN; HYPERCHOLESTEROLEMIA; KNEE OSTEOARTHRITIS; MULTIPLE MYELOMA; NONHUMAN; OPEN FRACTURE; OSSIFYING MYOSITIS; OSTEOARTHRITIS; OSTEOBLAST; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TISSUE ENGINEERING;

ANIMALS; ARTHRITIS; BONE AND BONES; BONE DEVELOPMENT; BONE DISEASES; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BONE RESORPTION; FRACTURE HEALING; HUMANS; JOINT DISEASES; OSTEOPOROSIS;

EID: 84874224849     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.06.003     Document Type: Review

References (173)

1. Wozney J.M. The bone morphogenetic protein family and osteogenesis. Molecular Reproduction and Development 1992, 32:160-167.
2. Guo X., Wang X.F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Research 2009, 19:71-88.
3. Urist M.R. Bone morphogenetic protein: the molecularization of skeletal system development. Journal of Bone and Mineral Research 1997, 12:343-346.
4. Li X., Cao X. BMP signaling and skeletogenesis. Annals of the New York Academy of Sciences 2006, 1068:26-40.
5. Yamaguchi A., Ishizuya T., Kintou N., et al. Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochemical and Biophysical Research Communications 1996, 220:366-371.
6. Yoon B.S., Lyons K.M. Multiple functions of BMPs in chondrogenesis. Journal of Cellular Biochemistry 2004, 93:93-103.
7. Huang H., Song T.J., Li X., et al. BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:12670-12675.
8. Kang Q., Song W.X., Luo Q., et al. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells and Development 2009, 18:545-559.
9. Canalis E., Economides A.N., Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocrine Reviews 2003, 24:218-235.
10. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors 2004, 22:233-241.
11. Lowery J.W., de Caestecker M.P. BMP signaling in vascular development and disease. Cytokine and Growth Factor Reviews 2010, 21:287-298.
12. Miyazono K. Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone 1999, 25:91-93.
13. Nohe A., Hassel S., Ehrlich M., et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. Journal of Biological Chemistry 2002, 277:5330-5338.
14. Lavery K., Swain P., Falb D., Alaoui-Ismaili M.H. BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Journal of Biological Chemistry 2008, 283:20948-20958.
15. Bonor J., Adams E.L., Bragdon B., Moseychuk O., Czymmek K.J., Nohe A. Initiation of BMP2 signaling in domains on the plasma membrane. Journal of Cellular Physiology 2012, 227:2880-2888.
16. Attisano L., Wrana J.L. Signal transduction by the TGF-beta superfamily. Science 2002, 296:1646-1647.
17. Lai C.F., Cheng S.L. Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-beta in normal human osteoblastic cells. Journal of Biological Chemistry 2002, 277:15514-15522.
18. Celil A.B., Campbell P.G. BMP-2 and insulin-like growth factor-I mediate Osterix (Osx) expression in human mesenchymal stem cells via the MAPK and protein kinase D signaling pathways. Journal of Biological Chemistry 2005, 280:31353-31359.
19. Gazzerro E., Minetti C. Potential drug targets within bone morphogenetic protein signaling pathways. Current Opinion in Pharmacology 2007, 7:325-333.
20. Gazzerro E., Gangji V., Canalis E. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. Journal of Clinical Investigation 1998, 102:2106-2114.
21. Pereira R.C., Economides A.N., Canalis E. Bone morphogenetic proteins induce gremlin, a protein that limits their activity in osteoblasts. Endocrinology 2000, 141:4558-4563.
22. Gazzerro E., Pereira R.C., Jorgetti V., Olson S., Economides A.N., Canalis E. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 2005, 146:655-665.
23. Li X., Zhang Y., Kang H., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Journal of Biological Chemistry 2005, 280:19883-19887.
24. Onichtchouk D., Chen Y.G., Dosch R., et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 1999, 401:480-485.
25. Ishida W., Hamamoto T., Kusanagi K., et al. Smad6 is a Smad1/5-induced smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter. Journal of Biological Chemistry 2000, 275:6075-6079.
26. Briones-Orta M.A., Tecalco-Cruz A.C., Sosa-Garrocho M., Caligaris C., Macias-Silva M. Inhibitory Smad7: emerging roles in health and disease. Current Molecular Pharmacology 2011, 4:141-153.
27. Luo K. Negative regulation of BMP signaling by the ski oncoprotein. Journal of Bone and Joint Surgery 2003, 85-A(Suppl. 3):39-43.
28. Yoshida Y., Tanaka S., Umemori H., et al. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 2000, 103:1085-1097.
29. Suzuki A., Raya A., Kawakami Y., et al. Nanog binds to Smad1 and blocks bone morphogenetic protein-induced differentiation of embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:10294-10299.
30. Kaneki H., Guo R., Chen D., et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. Journal of Biological Chemistry 2006, 281:4326-4333.
31. Cao X., Chen D. The BMP signaling and in vivo bone formation. Gene 2005, 357:1-8.
32. Zaidi M. Skeletal remodeling in health and disease. Nature Medicine 2007, 13:791-801.
33. Nakashima K., Zhou X., Kunkel G., et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
34. Franceschi R.T., Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. Journal of Cellular Biochemistry 2003, 88:446-454.
35. Lee M.H., Kim Y.J., Kim H.J., et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. Journal of Biological Chemistry 2003, 278:34387-34394.
36. Kamiya N. The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Current Molecular Pharmacology 2011.
37. Kamiya N., Kaartinen V.M., Mishina Y. Loss-of-function of ACVR1 in osteoblasts increases bone mass and activates canonical Wnt signaling through suppression of Wnt inhibitors SOST and DKK1. Biochemical and Biophysical Research Communications 2011, 414:326-330.
38. Tachi K., Takami M., Zhao B., et al. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-kappaB ligand expression in osteoblasts. Cell and Tissue Research 2010, 342:213-220.
39. Sato M.M., Nakashima A., Nashimoto M., Yawaka Y., Tamura M. Bone morphogenetic protein-2 enhances Wnt/beta-catenin signaling-induced osteoprotegerin expression. Genes to Cells 2009, 14:141-153.
40. Takahashi N., Maeda K., Ishihara A., Uehara S., Kobayashi Y. Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. Frontiers in Bioscience 2011, 16:21-30.
41. Qiang Y.W., Chen Y., Stephens O., et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008, 112:196-207.
42. Fujita K., Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Molecular Cancer 2007, 6:71.
43. Jensen E.D., Pham L., Billington C.J., et al. Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. Journal of Cellular Biochemistry 2010, 109:672-682.
44. Giannoudis P.V., Psarakis S., Kanakaris N.K., Pape H.C. Biological enhancement of bone healing with Bone Morphogenetic Protein-7 at the clinical setting of pelvic girdle non-unions. Injury 2007, 38(Suppl. 4):S43-S48.
45. Kaplan F.S., Pignolo R.J., Shore E.M. The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine and Growth Factor Reviews 2009, 20:399-407.
46. van Dinther M., Visser N., de Gorter D.J., et al. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. Journal of Bone and Mineral Research 2010, 25:1208-1215.
47. Chakkalakal S.A., Zhang D., Culbert A.L., et al. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. Journal of Bone Minerals Research 2012.
48. Kaplan F.S., Lounev V.Y., Wang H., Pignolo R.J., Shore E.M. Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis. Annals of the New York Academy of Sciences 2011, 1237:5-10.
49. Jackson W.M., Aragon A.B., Onodera J., et al. Cytokine expression in muscle following traumatic injury. Journal of Orthopaedic Research 2011, 29:1613-1620.
50. Tanaka H., Nagai E., Murata H., et al. Involvement of bone morphogenic protein-2 (BMP-2) in the pathological ossification process of the spinal ligament. Rheumatology 2001, 40:1163-1168.
51. Bandyopadhyay A., Tsuji K., Cox K., Harfe B.D., Rosen V., Tabin C.J. Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. PLoS Genet 2006, 2:e216.
52. Solloway M.J., Dudley A.T., Bikoff E.K., Lyons K.M., Hogan B.L., Robertson E.J. Mice lacking Bmp6 function. Developmental Genetics 1998, 22:321-339.
53. Tsuji K., Cox K., Gamer L., Graf D., Economides A., Rosen V. Conditional deletion of BMP7 from the limb skeleton does not affect bone formation or fracture repair. Journal of Orthopaedic Research 2010, 28:384-389.
54. Daluiski A., Engstrand T., Bahamonde M.E., et al. Bone morphogenetic protein-3 is a negative regulator of bone density. Nature Genetics 2001, 27:84-88.
55. Kokabu S., Gamer L., Cox K., et al. BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b. Molecular Endocrinology 2012, 26:87-94.
56. Devlin R.D., Du Z., Pereira R.C., et al. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 2003, 144:1972-1978.
57. Gazzerro E., Smerdel-Ramoya A., Zanotti S., et al. Conditional deletion of gremlin causes a transient increase in bone formation and bone mass. Journal of Biological Chemistry 2007, 282:31549-31557.
58. Lana D.P., Leferovich J.M., Kelly A.M., Hughes S.H. Selective expression of a ski transgene affects IIb fast muscles and skeletal structure. Developmental Dynamics 1996, 205:13-23.
59. Zhao M., Qiao M., Harris S.E., Oyajobi B.O., Mundy G.R., Chen D. Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. Journal of Biological Chemistry 2004, 279:12854-12859.
60. Yamashita M., Ying S.X., Zhang G.M., et al. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 2005, 121:101-113.
61. Kamiya N., Ye L., Kobayashi T., et al. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. Journal of Bone and Mineral Research 2008, 23:2007-2017.
62. Kamiya N., Kobayashi T., Mochida Y., et al. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. Journal of Bone and Mineral Research 2010, 25:200-210.
63. Okamoto M., Murai J., Imai Y., et al. Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice. Journal of Bone and Mineral Research 2011, 26:2511-2522.
64. Sotillo Rodriguez J.E., Mansky K.C., Jensen E.D., et al. Enhanced osteoclastogenesis causes osteopenia in twisted gastrulation-deficient mice through increased BMP signaling. Journal of Bone and Mineral Research 2009, 24:1917-1926.
65. Yi S.E., Daluiski A., Pederson R., Rosen V., Lyons K.M. The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development 2000, 127:621-630.
66. Zhao M., Harris S.E., Horn D., et al. Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. Journal of Cell Biology 2002, 157:1049-1060.
67. Yang C., Yang L., Wan M., Cao X. Generation of a mouse model with expression of bone morphogenetic protein type II receptor lacking the cytoplasmic domain in osteoblasts. Annals of the New York Academy of Sciences 2010, 1192:286-291.
68. Wang M., Jin H., Tang D., Huang S., Zuscik M.J., Chen D. Smad1 plays an essential role in bone development and postnatal bone formation. Osteoarthritis and Cartilage 2011, 19:751-762.
69. Xing L., Zhang M., Chen D. Smurf control in bone cells. Journal of Cellular Biochemistry 2010, 110:554-563.
70. Styrkarsdottir U., Cazier J.B., Kong A., et al. Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biology 2003, 1:E69.
71. Reneland R.H., Mah S., Kammerer S., et al. Association between a variation in the phosphodiesterase 4D gene and bone mineral density. BMC Medical Genetics 2005, 6:9.
72. Medici M., van Meurs J.B., Rivadeneira F., et al. BMP-2 gene polymorphisms and osteoporosis: the Rotterdam Study. Journal of Bone and Mineral Research 2006, 21:845-854.
73. Ozkan Z.S., Deveci D., Onalan Etem E., Yuce H. Lack of effect of bone morphogenetic protein 2 and 4 gene polymorphisms on bone density in postmenopausal Turkish women. Genetic and Molecular Research 2010, 9:2311-2316.
74. Moffett S.P., Dillon K.A., Yerges L.M., et al. Identification and association analysis of single nucleotide polymorphisms in the human noggin (NOG) gene and osteoporosis phenotypes. Bone 2009, 44:999-1002.
75. Cho T.J., Gerstenfeld L.C., Einhorn T.A. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. Journal of Bone and Mineral Research 2002, 17:513-520.
76. Kidd L.J., Stephens A.S., Kuliwaba J.S., Fazzalari N.L., Wu A.C., Forwood M.R. Temporal pattern of gene expression and histology of stress fracture healing. Bone 2010, 46:369-378.
77. Garcia P., Pieruschka A., Klein M., et al. Temporal and spatial vascularization patterns of unions and nonunions: role of vascular endothelial growth factor and bone morphogenetic proteins. Journal of Bone and Joint Surgery 2012, 94:49-58.
78. Fajardo M., Liu C.J., Egol K. Levels of expression for BMP-7 and several BMP antagonists may play an integral role in a fracture nonunion: a pilot study. Clinical Orthopaedics and Related Research 2009, 467:3071-3078.
79. Kloen P., Lauzier D., Hamdy R.C. Co-expression of BMPs and BMP-inhibitors in human fractures and non-unions. Bone 2012, 51:59-68.
80. White A.P., Vaccaro A.R., Hall J.A., Whang P.G., Friel B.C., McKee M.D. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. International Orthopaedics 2007, 31:735-741.
81. Chen A.L., Fang C., Liu C., Leslie M.P., Chang E., Di Cesare P.E. Expression of bone morphogenetic proteins, receptors, and tissue inhibitors in human fetal, adult, and osteoarthritic articular cartilage. Journal of Orthopaedic Research 2004, 22:1188-1192.
82. Bobacz K., Gruber R., Soleiman A., Erlacher L., Smolen J.S., Graninger W.B. Expression of bone morphogenetic protein 6 in healthy and osteoarthritic human articular chondrocytes and stimulation of matrix synthesis in vitro. Arthritis and Rheumatism 2003, 48:2501-2508.
83. Nakase T., Miyaji T., Tomita T., et al. Localization of bone morphogenetic protein-2 in human osteoarthritic cartilage and osteophyte. Osteoarthritis and Cartilage 2003, 11:278-284.
84. Fukui N., Zhu Y., Maloney W.J., Clohisy J., Sandell L.J. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. Journal of Bone and Joint Surgery 2003, 85-A(Suppl. 3):59-66.
85. Dell'Accio F., De Bari C., El Tawil N.M., et al. Activation of WNT and BMP signaling in adult human articular cartilage following mechanical injury. Arthritis Research and Therapy 2006, 8:R139.
86. Blaney Davidson E.N., Vitters E.L., van Lent P.L., van de Loo F.A., van den Berg W.B., van der Kraan P.M. Elevated extracellular matrix production and degradation upon bone morphogenetic protein-2 (BMP-2) stimulation point toward a role for BMP-2 in cartilage repair and remodeling. Arthritis Research and Therapy 2007, 9:R102.
87. Fan Z., Chubinskaya S., Rueger D.C., Bau B., Haag J., Aigner T. Regulation of anabolic and catabolic gene expression in normal and osteoarthritic adult human articular chondrocytes by osteogenic protein-1. Clinical and Experimental Rheumatology 2004, 22:103-106.
88. Flechtenmacher J., Huch K., Thonar E.J., et al. Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. Arthritis and Rheumatism 1996, 39:1896-1904.
89. Nishida Y., Knudson C.B., Knudson W. Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis. Osteoarthritis and Cartilage 2004, 12:374-382.
90. Im H.J., Pacione C., Chubinskaya S., Van Wijnen A.J., Sun Y., Loeser R.F. Inhibitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment- and interleukin-1beta-stimulated matrix metalloproteinase-13 expression in human chondrocytes. Journal of Biological Chemistry 2003, 278:25386-25394.
91. van Beuningen H.M., Glansbeek H.L., van der Kraan P.M., van den Berg W.B. Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation. Osteoarthritis and Cartilage 1998, 6:306-317.
92. Blaney Davidson E.N., Vitters E.L., van Beuningen H.M., van de Loo F.A., van den Berg W.B., van der Kraan P.M. Resemblance of osteophytes in experimental osteoarthritis to transforming growth factor beta-induced osteophytes: limited role of bone morphogenetic protein in early osteoarthritic osteophyte formation. Arthritis and Rheumatism 2007, 56:4065-4073.
93. Merrihew C., Kumar B., Heretis K., Rueger D.C., Kuettner K.E., Chubinskaya S. Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage. Journal of Orthopaedic Research 2003, 21:899-907.
94. Boon M.R., van der Horst G., van der Pluijm G., Tamsma J.T., Smit J.W., Rensen P.C. Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency. Cytokine and Growth Factor Reviews 2011, 22:221-229.
95. Honsawek S., Chayanupatkul M., Tanavalee A., et al. Relationship of plasma and synovial fluid BMP-7 with disease severity in knee osteoarthritis patients: a pilot study. International Orthopaedics 2009, 33:1171-1175.
96. Tardif G., Hum D., Pelletier J.P., Boileau C., Ranger P., Martel-Pelletier J. Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis and Rheumatism 2004, 50:2521-2530.
97. Tardif G., Pelletier J.P., Boileau C., Martel-Pelletier J. The BMP antagonists follistatin and gremlin in normal and early osteoarthritic cartilage: an immunohistochemical study. Osteoarthritis and Cartilage 2009, 17:263-270.
98. Lories R.J., Daans M., Derese I., et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis and Rheumatism 2006, 54:1736-1746.
99. Kaiser M., Haag J., Soder S., Bau B., Aigner T. Bone morphogenetic protein and transforming growth factor beta inhibitory Smads 6 and 7 are expressed in human adult normal and osteoarthritic cartilage in vivo and are differentially regulated in vitro by interleukin-1beta. Arthritis and Rheumatism 2004, 50:3535-3540.
100. Blaney Davidson E.N., Remst D.F., Vitters E.L., et al. Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. Journal of Immunology 2009, 182:7937-7945.
101. Blaney Davidson E.N., Vitters E.L., van der Kraan P.M., van den Berg W.B. Expression of transforming growth factor-beta (TGFbeta) and the TGFbeta signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation. Annals of the Rheumatic Diseases 2006, 65:1414-1421.
102. van der Kraan P.M., Blaney Davidson E.N., van den Berg W.B. Bone morphogenetic proteins and articular cartilage: to serve and protect or a wolf in sheep clothing's?. Osteoarthritis and Cartilage 2010, 18:735-741.
103. van der Kraan P.M., Blaney Davidson E.N., van den Berg W.B. A role for age-related changes in TGFbeta signaling in aberrant chondrocyte differentiation and osteoarthritis. Arthritis Research and Therapy 2010, 12:201.
104. Park M.C., Park Y.B., Lee S.K. Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis. Scandinavian Journal of Rheumatology 2008, 37:200-204.
105. Grcevic D., Jajic Z., Kovacic N., et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. Journal of Rheumatology 2010, 37:246-256.
106. Lories R.J., Derese I., Ceuppens J.L., Luyten F.P. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis and Rheumatism 2003, 48:2807-2818.
107. Bramlage C.P., Haupl T., Kaps C., et al. Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Research and Therapy 2006, 8:R58.
108. Daans M., Lories R.J., Luyten F.P. Dynamic activation of bone morphogenetic protein signaling in collagen-induced arthritis supports their role in joint homeostasis and disease. Arthritis Research and Therapy 2008, 10:R115.
109. Verschueren P.C., Lories R.J., Daans M., et al. Detection, identification and in vivo treatment responsiveness of bone morphogenetic protein (BMP)-activated cell populations in the synovium of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2009, 68:117-123.
110. Lories R.J., Derese I., Luyten F.P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. Journal of Clinical Investigation 2005, 115:1571-1579.
111. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer 2002, 2:584-593.
112. Dai J., Keller J., Zhang J., Lu Y., Yao Z., Keller E.T. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Research 2005, 65:8274-8285.
113. Lee Y., Schwarz E., Davies M., et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. Journal of Orthopaedic Research 2003, 21:62-72.
114. Bobinac D., Maric I., Zoricic S., et al. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croatian Medical Journal 2005, 46:389-396.
115. Schwaninger R., Rentsch C.A., Wetterwald A., et al. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. American Journal of Pathology 2007, 170:160-175.
116. Buijs J.T., Henriquez N.V., van Overveld P.G., et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Research 2007, 67:8742-8751.
117. Buijs J.T., Rentsch C.A., van der Horst G., et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. American Journal of Pathology 2007, 171:1047-1057.
118. Feeley B.T., Gamradt S.C., Hsu W.K., et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. Journal of Bone and Mineral Research 2005, 20:2189-2199.
119. Feeley B.T., Liu N.Q., Conduah A.H., et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. Journal of Bone and Mineral Research 2006, 21:1571-1580.
120. Secondini C., Wetterwald A., Schwaninger R., Thalmann G.N., Cecchini M.G. The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis. PLoS ONE 2011, 6:e16078.
121. Virk M.S., Alaee F., Petrigliano F.A., et al. Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion. Bone 2011, 48:578-587.
122. Tingart M., Beckmann J., Opolka A., et al. Influence of factors regulating bone formation and remodeling on bone quality in osteonecrosis of the femoral head. Calcified Tissue International 2008, 82:300-308.
123. Tingart M., Beckmann J., Opolka A., et al. Analysis of bone matrix composition and trabecular microarchitecture of the femoral metaphysis in patients with osteonecrosis of the femoral head. Journal of Orthopaedic Research 2009, 27:1175-1181.
124. Cui Q., Botchwey E.A. Emerging ideas: treatment of precollapse osteonecrosis using stem cells and growth factors. Clinical Orthopaedics and Related Research 2011, 469:2665-2669.
125. Vandermeer J.S., Kamiya N., Aya-ay J., Garces A., Browne R., Kim H.K. Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity. Journal of Bone and Joint Surgery 2011, 93:905-913.
126. May O., Schiopou D., Soenen M., et al. Ambulatory drilling for necrosis of the femoral head: intermediary results of a randomized study evaluating contribution of autologous bone marrow with and without BMP. Journal of Bone and Joint Surgery, British Volume 2011, 93-B(Suppl. IV):540.
127. Sampath T.K., Reddi A.H. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. Proceedings of the National Academy of Sciences of the United States of America 1981, 78:7599-7603.
128. Reddi A.H. Regulation of cartilage and bone differentiation by bone morphogenetic proteins. Current Opinion in Cell Biology 1992, 4:850-855.
129. Bessa P.C., Casal M., Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). Journal of Tissue Engineering and Regenerative Medicine 2008, 2:81-96.
130. Boerckel J.D., Kolambkar Y.M., Dupont K.M., et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials 2011, 32:5241-5251.
131. King G.N., Cochran D.L. Factors that modulate the effects of bone morphogenetic protein-induced periodontal regeneration: a critical review. Journal of Periodontology 2002, 73:925-936.
132. La W.G., Kang S.W., Yang H.S., et al. The efficacy of bone morphogenetic protein-2 depends on its mode of delivery. Artificial Organs 2010, 34:1150-1153.
133. La W.G., Kwon S.H., Lee T.J., Yang H.S., Park J., Kim B.S. The effect of the delivery carrier on the quality of bone formed via bone morphogenetic Protein-2. Artificial Organs 2012.
134. Yang H.S., La W.G., Cho Y.M., Shin W., Yeo G.D., Kim B.S. Comparison between heparin-conjugated fibrin and collagen sponge as bone morphogenetic protein-2 carriers for bone regeneration. Experimental and Molecular Medicine 2012.
135. Takahashi Y., Yamamoto M., Tabata Y. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and beta-tricalcium phosphate. Biomaterials 2005, 26:4856-4865.
136. Dimitriou R., Carr I.M., West R.M., Markham A.F., Giannoudis P.V. Genetic predisposition to fracture non-union: a case control study of a preliminary single nucleotide polymorphisms analysis of the BMP pathway. BMC Musculoskeletal Disorders 2011, 12:44.
137. Agarwal R., Williams K., Umscheid C.A., Welch W.C. Osteoinductive bone graft substitutes for lumbar fusion: a systematic review. Journal of Neurosurgery: Spine 2009, 11:729-740.
138. Garrison K.R., Shemilt I., Donell S., et al. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database of Systematic Reviews 2010, CD006950.
139. Toth J.M., Boden S.D., Burkus J.K., Badura J.M., Peckham S.M., McKay W.F. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine (Phila Pa 1976) 2009, 34:539-550.
140. Argintar E., Edwards S., Delahay J. Bone morphogenetic proteins in orthopaedic trauma surgery. Injury 2011, 42:730-734.
141. Hayashi M., Muneta T., Takahashi T., Ju Y.J., Tsuji K., Sekiya I. Intra-articular injections of bone morphogenetic protein-7 retard progression of existing cartilage degeneration. Journal of Orthopaedic Research 2010, 28:1502-1506.
142. Hunter D.J., Pike M.C., Jonas B.L., Kissin E., Krop J., McAlindon T. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskeletal Disorders 2010, 11:232.
143. Simic P., Culej J.B., Orlic I., et al. Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption. Journal of Biological Chemistry 2006, 281:25509-25521.
144. Drake M.T., Srinivasan B., Modder U.I., et al. Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone 2011, 49:349-355.
145. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. Journal of Clinical Investigation 1998, 102:274-282.
146. Kanazawa I., Yamaguchi T., Yano S., Hayashi K., Yamauchi M., Sugimoto T. Inhibition of the mevalonate pathway rescues the dexamethasone-induced suppression of the mineralization in osteoblasts via enhancing bone morphogenetic protein-2 signal. Hormone and Metabolic Research 2009, 41:612-616.
147. Hayashi K., Yamaguchi T., Yano S., et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochemical and Biophysical Research Communications 2009, 379:261-266.
148. Mundy G., Garrett R., Harris S., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
149. Hu H., Sung A., Zhao G., et al. Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochemical and Biophysical Research Communications 2006, 339:59-64.
150. Yue J., Zhang X., Dong B., Yang M. Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause 2010, 17:1071-1079.
151. Marie P.J., Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. European Journal of Endocrinology/European Federation of Endocrine Societies 2011, 165:1-10.
152. Breuil V., Amri E.Z., Panaia-Ferrari P., et al. Oxytocin and bone remodelling: relationships with neuropituitary hormones, bone status and body composition. Joint, Bone, Spine 2011, 78:611-615.
153. Tamma R., Colaianni G., Zhu L.L., et al. Oxytocin is an anabolic bone hormone. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:7149-7154.
154. Elabd C., Basillais A., Beaupied H., et al. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells 2008, 26:2399-2407.
155. Tang D.Z., Hou W., Zhou Q., et al. Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. Journal of Bone and Mineral Research 2010, 25:1234-1245.
156. Tang D.Z., Yang F., Yang Z., et al. Psoralen stimulates osteoblast differentiation through activation of BMP signaling. Biochemical and Biophysical Research Communications 2011, 405:256-261.
157. Lee S.U., Park S.J., Kwak H.B., Oh J., Min Y.K., Kim S.H. Anabolic activity of ursolic acid in bone: stimulating osteoblast differentiation in vitro and inducing new bone formation in vivo. Pharmacological Research 2008, 58:290-296.
158. Chang J.K., Hsu Y.L., Teng I.C., Kuo P.L. Piceatannol stimulates osteoblast differentiation that may be mediated by increased bone morphogenetic protein-2 production. European Journal of Pharmacology 2006, 551:1-9.
159. Hsu Y.L., Liang H.L., Hung C.H., Kuo P.L. Syringetin, a flavonoid derivative in grape and wine, induces human osteoblast differentiation through bone morphogenetic protein-2/extracellular signal-regulated kinase 1/2 pathway. Molecular Nutrition & Food Research 2009, 53:1452-1461.
160. Wu J.B., Fong Y.C., Tsai H.Y., Chen Y.F., Tsuzuki M., Tang C.H. Naringin-induced bone morphogenetic protein-2 expression via PI3K, Akt, c-Fos/c-Jun and AP-1 pathway in osteoblasts. European Journal of Pharmacology 2008, 588:333-341.
161. Yu P.B., Deng D.Y., Lai C.S., et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nature Medicine 2008, 14:1363-1369.
162. Hannallah D., Peng H., Young B., Usas A., Gearhart B., Huard J. Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model. Journal of Bone and Joint Surgery 2004, 86-A:80-91.
163. Tsialogiannis E., Polyzois I., Oak Tang Q., Pavlou G., Tsiridis E., Heliotis M. Targeting bone morphogenetic protein antagonists: in vitro and in vivo evidence of their role in bone metabolism. Expert Opinion on Therapeutic Targets 2009, 13:123-137.
164. Tsuchida K., Nakatani M., Uezumi A., Murakami T., Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocrine Journal 2008, 55:11-21.
165. Pearsall R.S., Canalis E., Cornwall-Brady M., et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:7082-7087.
166. Lotinun S., Pearsall R.S., Davies M.V., et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010, 46:1082-1088.
167. Ruckle J., Jacobs M., Kramer W., et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. Journal of Bone and Mineral Research 2009, 24:744-752.
168. Lotinun S., Pearsall R.S., Horne W.C., Baron R. Activin receptor signaling: a potential therapeutic target for osteoporosis. Current Molecular Pharmacology 2011.
169. Garrett I.R., Chen D., Gutierrez G., et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. Journal of Clinical Investigation 2003, 111:1771-1782.
170. Zangari M., Terpos E., Zhan F., Tricot G. Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treatment Reviews 2012.
171. Canalis E. Update in new anabolic therapies for osteoporosis. Journal of Clinical Endocrinology and Metabolism 2010, 95:1496-1504.
172. Ito Y., Fukushima H., Katagiri T., et al. Lactacystin, a proteasome inhibitor, enhances BMP-induced osteoblastic differentiation by increasing active Smads. Biochemical and Biophysical Research Communications 2011, 407:225-229.
173. Allendorph G.P., Read J.D., Kawakami Y., Kelber J.A., Isaacs M.J., Choe S. Designer TGFβ superfamily ligands with diversified functionality. PLoS ONE 2011, 6:e26402.